AI Summary & Key Takeaways
AI InsightFewer adverse events were observed in Group 1 than Group 2 (phlebitis, p=0.305; ecchymosis, p=0.396; analgesic use, p=0.013;amount of analgesic used, p<0.001; time to first analgesia requirement, p<0.001).Conclusion: Our study results suggest that the same clinical success with fewer complications (ecchymosis, phlebitis, and pain) and greaterpatient satisfaction can be achieved using a lower dose of NBCA in the treatment of venous insufficiency.
📌 3 Key Takeaways
Özet
Objectives: This study aims to investigate the therapeutic effect of N-butyl cyanoacrylate (NBCA) administration on the treatment successand patient comfort in patients with venous insufficiency.Patients and methods: Between March 2019 and June 2019, a total of 80 patients (29 males, 51 females; mean age 49.6±12.0 years;range, 25 to 81 years) diagnosed with great saphenous vein incompetence and underwent endovenous ablation with 1.5 mLNBCAwere included in this prospective, randomized study. The patients were equally divided into two groups as Group 1 (n=40) receiving 1.5 mL NBCA. The patients were invited for checks on the third day and first monthpost-procedurally and were evaluated in terms of potential complications. Post-procedural analgesic requirements, time to first analgesicrequirement, number of 500 mg paracetamol doses used over three days among patients requiring analgesia, and pain experienced using theVisual Analog Scale after the procedure and on the third day were recorded.Results: The mean lengths of vein segments subjected to NBCA application and ablation were 33 cm in Group 1 and 34 cm in Group 2(p=0.430). Fewer adverse events were observed in Group 1 than Group 2 (phlebitis, p=0.305; ecchymosis, p=0.396; analgesic use, p=0.013;amount of analgesic used, p<0.001; time to first analgesia requirement, p<0.001).Conclusion: Our study results suggest that the same clinical success with fewer complications (ecchymosis, phlebitis, and pain) and greaterpatient satisfaction can be achieved using a lower dose of NBCA in the treatment of venous insufficiency.